COPD
Current COPD Studies
AER-01-002
AER Study
Study Title
A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER-01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease
Study Duration
- Up to 10 weeks
Number of clinic visits
- Up to 7
Number of phone calls
- 1
Main Entry Criteria
- 40 to 80 years of age
- Confirmed diagnosis of COPD
- Participant has had less than 2 COPD exacerbations requiring hospitalization in the past year
There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.
Assessments
- ECG
- Blood pressure and pulse
- Spirometry
- Blood and urine tests
- Questionnaires
You will receive all study-related procedures, medications, and laboratory services at no cost. In addition, you will be reimbursed $130 per visit for your time and travel.
Study Status
- Currently recruiting – Spearwood and Osborne Park Locations
